We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Pui Ying
Chan
pyc1@sanger.ac.uk
Joanne
Doleman
researchgovernance@sanger.ac.uk
Dr
Pui Ying
Chan
pyc1@sanger.ac.uk
Malignant neoplasms of eye, brain and other parts of central nervous system
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Uveal melanomas are rare cancers that arise from pigment cells (melanocytes) in the eye. Like most rare cancers, limited interest in developing new therapies and a lack of clinical trials contributes towards relatively worse survival rates compared with common cancers. Following treatment of uveal melanoma with either surgical removal of the eye (enucleation) or local radiation (plaque brachytherapy), approximately half of all patients will develop metastases (new tumours). Most patients will die within a few months despite current therapies.
Conjunctival melanomas (cancer of the surface of the eye which lines the inside of the eyelids) are an extremely rare subset of eye cancers which also have poor survival outcomes once metastasised.
Modern DNA sequencing technologies enable researchers to identify mutations acquired during the lifetime of an individual (these are known as somatic mutations). Some of these somatic mutations occur in cancer-associated genes, and increase the risk of developing cancer. This study will use sequencing technologies to look to identify mutations associated with cancers of the eye. By sequencing at different stages of the disease we hope to build a timeline of the order of mutations that occur during eye cancer development. We will also generate cell line models to try and understand how these cancers develop, spread (metastasise) and respond to treatments.
We will also look at which somatic mutations are detectable in blood. Blood samples will be collected regularly from participants and circulating tumour DNA, (ctDNA, fragments of DNA released by tumours into the bloodstream) will be sequenced. We will determine whether the mutations present in ctDNA can be used as an indicator of disease progression.
This study will provide much needed insight into a rare and understudied cancer type, with the aim of improving the survival of patients by identifying key mutations to develop novel therapies against.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Clinical Laboratory Study;
You can take part if:
You may not be able to take part if:
Patients < 18 years of age.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Joanne
Doleman
researchgovernance@sanger.ac.uk
Dr
Pui Ying
Chan
pyc1@sanger.ac.uk
Dr
Pui Ying
Chan
pyc1@sanger.ac.uk
The study is sponsored by GENOME RESEARCH LIMITED and funded by Wellcome Trust .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 38077
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
